美国贸易代表办公室：新301条款调查将覆盖大多数主要贸易伙伴

Core Viewpoint - The U.S. Supreme Court has rejected tariffs imposed by the White House under the International Emergency Economic Powers Act, prompting the U.S. Trade Representative's Office (USTR) to initiate a new round of Section 301 investigations targeting the pharmaceutical and technology sectors [1][4]. Group 1: Investigation and Tariff Implications - The new Section 301 investigations will cover a wide range of issues, including industrial overcapacity, forced labor, drug pricing, and discrimination against U.S. tech companies and digital goods [1]. - The USTR plans to set an accelerated timeline for these investigations, indicating that the process will not be lengthy [2]. - If unfair trade practices are identified, tariffs will be one of the tools available to address these issues, potentially leading to increased import costs for affected industries [3]. Group 2: Policy Response to Supreme Court Ruling - The initiation of the Section 301 investigations is a direct response to the Supreme Court's ruling that invalidated tariffs imposed under the International Emergency Economic Powers Act, which ranged from 10% to 50% [4]. - The Trump administration is employing a "combination punch" strategy to fill the policy gap left by the Supreme Court's decision, emphasizing that many tariffs imposed under other legal frameworks remain effective [5]. Group 3: Existing Trade Agreements - Despite ongoing legal battles, the USTR reassures that existing trade agreements negotiated by the Trump administration remain intact and effective [6]. - The USTR has successfully reached framework trade agreements with several countries and signed agreements with seven others, indicating a stable trade foundation despite tariff adjustments [8].